Abstract
The objective of this observational study in nine European countries was to establish the current cost of MS at different levels of disease severity. The study used a prevalence-based bottom-up to estimate costs from a societal perspective. Patients were recruited via patient organizations and neurology centres and asked by mail to complete a detailed questionnaire concerning their resource consumption, work capacity, quality of life and current disease status. Resources included all health-care and social services, personal expenditures, informal care and temporary or definitive work absence. Quality of life was collected as utility and disease information collected related to functional capacity, relapses and fatigue. The data were analyzed separately for each country, using local unit costs but a fully standardized methodology. A total of 13 186 patients at all levels of disease severity participated in the survey, with an average response rate of around 40% (range 20–75%).
This paper describes the methodology used for the study, while results are presented in the individual country reports.
Similar content being viewed by others
References
Holmes J, Madgwick T, Bates D (1995) The cost of multiple sclerosis. Br J Med Econ 8: 181–193
Henriksson F, Jönsson B (1998) The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 13: 597–606
Carton H, Loos R, Pacolet J, Versieck K, Vlietinck R (1998) Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 64: 444–450
Kobelt G, Lindgren P, Parkin D et al. (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. SSE/EFI Working Paper Series in Economics and Finance No. 398. Stockholm School of Economics, Stockholm, Sweden
Henriksson F, Fredrikson S, Masterman T, Jönsson B (2001) Costs, quality of life and disease severity in multiple sclerosis. A cross-sectional study in Sweden. Eur J Neurol 8: 27–35
Kobelt G, Lindgren P, Smala A, Jönsson B, Group GCoMS (2001) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur J Health Econ 2: 60–68
Amato MP, Battaglia MA, Caputo D et al. (2002) The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 249: 152–163
Russo P, Capone A, Paolillo A, Al E (2004) Cost analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Invest 24: 409–420
Kazas E, Grisouard R, Zanni J et al. (2003) Multiple sclerosis treatment with interferon beta: prevalence and cost of the public health fund in 2000. Rev Méd l’Assurance Maladie 34: 147–156
Kobelt G, Berg J, Atherley D, Hadjimichael O, Jönsson B (2004) Cost and quality of life in multiple sclerosis. A cross-sectional study in the USA. SSE/EFI Working Paper Series in Economics and Finance No. 594. Stockholm School of Economics, Stockholm, Sweden
Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B (2006) Costs and quality of life of multiple sclerosis in Europe. J Neurol (In press)
Miltenburger C, Kobelt G (2002) Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 104: 272–275
Jönsson B (1996) Quality of life and health economics. Where is the link? Scand J Gastroenterol Suppl 221: 33–36
Torrance G (1986) Measurement of health state utilities for economic appraisal. A review. J Health Econ 5: 1–30
Kobelt G (1996) Health economics: introduction to economic evaluation. Office of Health Economics: London, UK
Drummond M, O’Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care. Kluwer Academic Publishers: Boston, MA, USA
Johannesson M (1996) Outcome measurement in economic evaluation. Health Econ 5: 279–296
The EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16: 199–208
Torrance G (1992) Multi-attribute value and utility functions for a comprehensive health status classification system. McMasters University: Toronto, Ontario, Canada
Dolan P, Gudex C, Kind P, Williams A (1995) A social tariff for EuroQol: Results from a UK general population survey. Centre for Health Economics, University of York: York, UK
Henriksson F, Fredrikson S, Jönsson B (2000) Costs, quality of life and disease severity in multiple sclerosis – a cross-sectional study in Sweden. SSE/EFI Working Paper Series in Economics and Finance No. 361. Stockholm School of Economics, Stockholm, Sweden
Kobelt G, Lindgren P, Smala A, Jönsson B, Group Gms (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. SSE/EFI Working Paper Series in Economics and Finance No. 399. Stockholm School of Economics; Stockholm, Sweden
Eichler H, Kong S, Gerth W, Al E (2004) Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectivness thresholds expected to emerge? Val Health 7: 518–528
Kurtzke J (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444–1452
Orlewska E, Mierzejewski P, Zaborski J et al. (2005) A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol 12: 31–339
Hohol M, Orav E, Weiner H (1995) Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 45: 251–155
Schwartz C, Vollmer T, Lee H (1999) North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology 52: 63–71
Lublin F, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46: 907–911
Weinshenker B, Al E (1991) The natural history of multiple sclerosis I and II. Brain 114: 1045–1065
Kurtzke J (1955) A new scale for evaluating disability in multiple sclerosis. Neurology 5: 580–583
Kobelt G, Jönsson L, Fredrikson S (2003) A new disease model to estimate the cost of disease progression for different types of MS and different subgroups of patients. Eur J Health Econ 4: 50–59
Koopmanschap M, Rutten F, Vanineveld B, Vanroijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14: 171–189
Interessenkonflikt
Keine Angaben
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kobelt, G., Berg, J., Lindgren, P. et al. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 7 (Suppl 2), 5–13 (2006). https://doi.org/10.1007/s10198-006-0365-y
Issue Date:
DOI: https://doi.org/10.1007/s10198-006-0365-y